- Boston Scientific press release ( NYSE: BSX ): Q2 Non-GAAP EPS of $0.44 beats by $0.02 .
- Revenue of $3.24B (+5.5% Y/Y) beats by $20M .
- MedSurg: 4.5 percent reported, 7.9 percent operational and 4.8 percent organic
- Cardiovascular: 6.0 percent reported, 10.8 percent operational and 7.8 percent organic
- Achieved the following regional net sales growth/(decline), compared to the prior year period:
- U.S.: 7.4 percent reported and operational
- EMEA (Europe, Middle East and Africa): (0.3) percent reported and 11.8 percent operational
- APAC (Asia-Pacific): 1.9 percent reported and 11.2 percent operational
- Emerging Markets: 18.9 percent reported and 26.0 percent operational
-
FY22 Outlook: The company now estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 6.5 to 7.5 percent on a reported basis from prior outlook of approximately 7 to 9 percent vs. 7.85% consensus, and approximately 8 to 9 percent on an organic basis. The company now estimates EPS on a GAAP basis in a range of $0.69 to $0.76 and estimates adjusted EPS, excluding certain charges (credits), of $1.74 to $1.77 from prior outlook of $1.74-$1.79 vs. $1.76 consensus.
Q3 Outlook: The company estimates net sales growth for the third quarter of 2022, versus the prior year period, to be in a range of approximately 6 to 8 percent on a reported basis vs. 9.21% consensus and approximately 8 to 10 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $0.20 to $0.24 and adjusted EPS, excluding certain charges (credits), of $0.43 to $0.45 vs. $0.45 consensus.
For further details see:
Boston Scientific Non-GAAP EPS of $0.44 beats by $0.02, revenue of $3.24B beats by $20M